|
Gene: DDO |
Gene summary for DDO |
Gene summary. |
Gene information | Species | Human | Gene symbol | DDO | Gene ID | 8528 |
Gene name | D-aspartate oxidase | |
Gene Alias | DASOX | |
Cytomap | 6q21 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q99489 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8528 | DDO | P2T-E | Human | Esophagus | ESCC | 4.75e-03 | 5.82e-02 | 0.1177 |
8528 | DDO | P10T-E | Human | Esophagus | ESCC | 9.63e-120 | 2.16e+00 | 0.116 |
8528 | DDO | P28T-E | Human | Esophagus | ESCC | 2.01e-75 | 1.43e+00 | 0.1149 |
8528 | DDO | P39T-E | Human | Esophagus | ESCC | 4.47e-51 | 9.96e-01 | 0.0894 |
8528 | DDO | P49T-E | Human | Esophagus | ESCC | 5.06e-29 | 2.55e+00 | 0.1768 |
8528 | DDO | P56T-E | Human | Esophagus | ESCC | 1.26e-29 | 3.27e+00 | 0.1613 |
8528 | DDO | P62T-E | Human | Esophagus | ESCC | 1.18e-02 | 9.19e-02 | 0.1302 |
8528 | DDO | P74T-E | Human | Esophagus | ESCC | 1.47e-89 | 2.42e+00 | 0.1479 |
8528 | DDO | P80T-E | Human | Esophagus | ESCC | 1.48e-03 | 1.49e-01 | 0.155 |
8528 | DDO | P89T-E | Human | Esophagus | ESCC | 7.68e-36 | 2.50e+00 | 0.1752 |
8528 | DDO | P104T-E | Human | Esophagus | ESCC | 2.51e-15 | 1.64e+00 | 0.0931 |
8528 | DDO | P128T-E | Human | Esophagus | ESCC | 6.19e-78 | 2.53e+00 | 0.1241 |
8528 | DDO | P130T-E | Human | Esophagus | ESCC | 1.22e-131 | 3.24e+00 | 0.1676 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ESCC: Esophageal squamous cell carcinoma | |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00421108 | Cervix | CC | T cell activation | 107/2311 | 487/18723 | 1.24e-09 | 1.46e-07 | 107 |
GO:003164710 | Cervix | CC | regulation of protein stability | 63/2311 | 298/18723 | 1.14e-05 | 2.45e-04 | 63 |
GO:004211013 | Cervix | HSIL_HPV | T cell activation | 48/737 | 487/18723 | 5.12e-09 | 7.61e-07 | 48 |
GO:003164715 | Cervix | HSIL_HPV | regulation of protein stability | 31/737 | 298/18723 | 8.69e-07 | 4.19e-05 | 31 |
GO:004211022 | Cervix | N_HPV | T cell activation | 39/534 | 487/18723 | 7.04e-09 | 1.58e-06 | 39 |
GO:003164725 | Cervix | N_HPV | regulation of protein stability | 17/534 | 298/18723 | 5.47e-03 | 3.90e-02 | 17 |
GO:0031647 | Colorectum | AD | regulation of protein stability | 108/3918 | 298/18723 | 6.33e-10 | 5.08e-08 | 108 |
GO:0018279 | Colorectum | AD | protein N-linked glycosylation via asparagine | 15/3918 | 23/18723 | 5.47e-06 | 1.40e-04 | 15 |
GO:0018196 | Colorectum | AD | peptidyl-asparagine modification | 15/3918 | 24/18723 | 1.18e-05 | 2.62e-04 | 15 |
GO:0006487 | Colorectum | AD | protein N-linked glycosylation | 25/3918 | 65/18723 | 9.12e-04 | 8.71e-03 | 25 |
GO:0006486 | Colorectum | AD | protein glycosylation | 64/3918 | 226/18723 | 4.86e-03 | 3.27e-02 | 64 |
GO:0043413 | Colorectum | AD | macromolecule glycosylation | 64/3918 | 226/18723 | 4.86e-03 | 3.27e-02 | 64 |
GO:0070085 | Colorectum | AD | glycosylation | 67/3918 | 240/18723 | 5.78e-03 | 3.67e-02 | 67 |
GO:00316471 | Colorectum | SER | regulation of protein stability | 86/2897 | 298/18723 | 2.56e-09 | 2.42e-07 | 86 |
GO:00182791 | Colorectum | SER | protein N-linked glycosylation via asparagine | 9/2897 | 23/18723 | 5.20e-03 | 3.95e-02 | 9 |
GO:00181961 | Colorectum | SER | peptidyl-asparagine modification | 9/2897 | 24/18723 | 7.19e-03 | 4.99e-02 | 9 |
GO:00316472 | Colorectum | MSS | regulation of protein stability | 103/3467 | 298/18723 | 2.52e-11 | 3.49e-09 | 103 |
GO:00182792 | Colorectum | MSS | protein N-linked glycosylation via asparagine | 13/3467 | 23/18723 | 5.21e-05 | 9.31e-04 | 13 |
GO:00181962 | Colorectum | MSS | peptidyl-asparagine modification | 13/3467 | 24/18723 | 9.44e-05 | 1.49e-03 | 13 |
GO:00064871 | Colorectum | MSS | protein N-linked glycosylation | 23/3467 | 65/18723 | 9.47e-04 | 9.54e-03 | 23 |
Page: 1 2 3 4 5 6 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa041467 | Esophagus | ESCC | Peroxisome | 55/4205 | 82/8465 | 1.04e-03 | 3.27e-03 | 1.68e-03 | 55 |
hsa0414612 | Esophagus | ESCC | Peroxisome | 55/4205 | 82/8465 | 1.04e-03 | 3.27e-03 | 1.68e-03 | 55 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DDO | SNV | Missense_Mutation | novel | c.518N>T | p.Ala173Val | p.A173V | Q99489 | protein_coding | tolerated(0.24) | benign(0.001) | TCGA-VP-A87B-01 | Prostate | prostate adenocarcinoma | Male | <65 | 8 | Hormone Therapy | leuprolide | SD |
DDO | SNV | Missense_Mutation | c.59N>G | p.Gln20Arg | p.Q20R | Q99489 | protein_coding | tolerated_low_confidence(0.86) | benign(0.04) | TCGA-BR-4201-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | SD | |
DDO | SNV | Missense_Mutation | c.457N>G | p.Lys153Glu | p.K153E | Q99489 | protein_coding | tolerated(0.53) | possibly_damaging(0.574) | TCGA-BR-7851-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
DDO | SNV | Missense_Mutation | c.347N>C | p.Gly116Ala | p.G116A | Q99489 | protein_coding | deleterious(0.03) | possibly_damaging(0.663) | TCGA-BR-A4J8-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | CR | |
DDO | SNV | Missense_Mutation | c.194A>C | p.Lys65Thr | p.K65T | Q99489 | protein_coding | deleterious(0.04) | benign(0.184) | TCGA-CG-4444-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
DDO | SNV | Missense_Mutation | c.194A>C | p.Lys65Thr | p.K65T | Q99489 | protein_coding | deleterious(0.04) | benign(0.184) | TCGA-HU-A4GH-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
DDO | SNV | Missense_Mutation | rs140929618 | c.959C>T | p.Ala320Val | p.A320V | Q99489 | protein_coding | tolerated(0.71) | benign(0) | TCGA-HU-A4GX-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | SD |
DDO | deletion | Frame_Shift_Del | novel | c.71delN | p.Phe24SerfsTer124 | p.F24Sfs*124 | Q99489 | protein_coding | TCGA-VQ-A91K-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | CR | ||
DDO | SNV | Missense_Mutation | novel | c.254C>A | p.Pro85Gln | p.P85Q | Q99489 | protein_coding | tolerated(0.05) | possibly_damaging(0.527) | TCGA-E8-A2EA-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DDO | SNV | Missense_Mutation | novel | c.821N>A | p.Pro274Gln | p.P274Q | Q99489 | protein_coding | tolerated(0.19) | probably_damaging(0.985) | TCGA-EM-A2CJ-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8528 | DDO | DRUGGABLE GENOME | topotecan | TOPOTECAN | 24444404 | |
8528 | DDO | DRUGGABLE GENOME | MALONIC ACID | MALONIC ACID | 26322531 | |
8528 | DDO | DRUGGABLE GENOME | 5-AMINONICOTINIC ACID | CHEMBL1491941 | 26322531 |
Page: 1 |